China Medical System: NDA for Additional Rheumatoid Arthritis Indication of Methotrexate Injection Approved in China China Medical System Holdings Ltd. Aug 05, 2024 23:00 JST Read More
Airlangga Alumnus Provides Digital Journalism Inspiration Airlangga University Aug 02, 2024 18:00 JST Read More
Hitachi High-Tech Acquires Majority Interest in Nabsys Hitachi, Ltd. Aug 01, 2024 16:51 HKT/SGT Read More
New Clinical Data Demonstrates Three Years of Continuous Treatment with Dual-Acting LEQEMBI (lecanemab-irmb) Continues to Significantly Benefit Early Alzheimer's Disease Patients Presented at AAIC 2024 Eisai Jul 31, 2024 12:59 HKT/SGT Read More
Update on Regulatory Review of Lecanemab for Early Alzheimer's Disease in the European Union Eisai Jul 29, 2024 16:59 HKT/SGT Read More
Eisai and EcoNaviSta Enter into Business Alliance Agreement Aimed at Building a Dementia Ecosystem and Commence Collaboration Eisai Jul 25, 2024 09:30 HKT/SGT Read More
Eisai to Present Dual-Acting Lecanemab Three-Year Efficacy and Safety Data and Discuss Long-Term Outcomes of Continued Treatment at the Alzheimer's Association International Conference 2024 Eisai Jul 23, 2024 19:23 HKT/SGT Read More
VitalLife and Bumrungrad International Hospital in Thailand Launch NEC's FonesVisuas Test: First Major Deployment Outside Japan, Revolutionizing Disease Risk Prediction NEC Corporation Jul 18, 2024 14:34 HKT/SGT Read More
China Medical System (867.HK) Reincluded in S&P Global Sustainability Yearbook (China Edition) and Maintained MSCI ESG "AA" Rating China Medical System Holdings Ltd. Jul 16, 2024 21:00 JST Read More
"LEQEMBI" (Lecanemab) Approved for the Treatment of Alzheimer's Disease in Israel Eisai Jul 12, 2024 11:56 HKT/SGT Read More
LEQEMBI (Lecanemab) Approved for the Treatment of Alzheimer's Disease in Hong Kong Eisai Jul 11, 2024 09:00 HKT/SGT Read More
Eisai Announces Move to Solo Development and Commercialization of Farletuzumab Ecteribulin (FZEC) Antibody Drug Conjugate (ADC) Eisai Jul 02, 2024 12:01 HKT/SGT Read More
Eisai: "LEQEMBI" (Lecanemab) for the Treatment of Alzheimer's Disease Launched in China Eisai Jun 28, 2024 14:57 HKT/SGT Read More
ONERHT Foundation's 7th GAIL Forum highlights urgent need to incorporate sustainability into everyday practices and company culture ONERHT Foundation Jun 26, 2024 18:04 JST Read More
China Medical System Completes Dosing of the First Subject in Phase III Bridging Trial of Ruxolitinib Cream in Atopic Dermatitis in China China Medical System Holdings Ltd. Jun 25, 2024 21:46 JST Read More
Eisai Continues Contract for FY2024 Dementia Examination Project by Tokyo Bunkyo City Eisai Jun 21, 2024 14:35 HKT/SGT Read More
Fujitsu Japan and Kamoenai Village in Hokkaido raise awareness for oral and dental healthcare Fujitsu Ltd Jun 19, 2024 13:20 HKT/SGT Read More
